サイネオス・ヘルス、University Malaya Medical Centreと契約を締結し、マレーシアでのCatalyst Site Programを拡大

MORRISVILLE, N.C. – August, 8 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has entered into an agreement with University Malaya Medical Centre, expanding the Company’s clinical trial capabilities across a broader range of therapeutic areas in Malaysia.

The agreement, where University Malaya Medical Centre now joins the Syneos Health Catalyst Site Program, fast tracks trial start up and enhances the clinical trial experience. Introduced in 2016 to strengthen collaborations with clinical research sites worldwide, the Catalyst Site Program harnesses insights from sites across the globe to drive continuous improvement and develop best practices in clinical research delivery. 

“Syneos Health is committed to building longstanding, productive site relationships. Leveraging our deep site relationships, we can help customers maneuver the region’s highly regulated and complex operating environment to deliver consistent quality, predictable results, and streamlined processes in clinical trials,” said Serena Chan, Head of Asia Pacific, Clinical Operations and General Manager Southeast Asia, Clinical Development, Syneos Health. “We look forward to working closely with University Malaya Medical Centre as part of the Catalyst Site Program.”

Syneos Health has relationships with more than 100 Catalyst sites worldwide and the Company has been acknowledged by the Society for Clinical Research Sites as a recipient of the Eagle Award for demonstrating dedication to establishing strong site partnerships.

“We are proud to join the Syneos Health Catalyst Site Program,” said Prof. Dr Nazirah Hasnan, Director of University Malaya Medical Centre. “Through this collaboration, we’re helping to streamline the clinical trial process to provide better delivery execution, improved quality, and predictability. This program will help facilitate accelerated knowledge transfer and develop new and more effective techniques.”

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. 臨床、メディカルアフェアーズ、およびコマーシャル事業に関する独自のインサイトを最新の市場の実態に対応できるように変換しています。  

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. 

Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. 

サイネオス・ヘルスは、同僚、お客様、患者様、コミュニティ、環境に配慮する、多様で公平、かつ包括的な社風を支持しています。  

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Syneos Investor Relations Contact:  Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 [email protected]

Syneos Press/Media Contact: Gary Gatyas Executive Director, External Communications +1 908 763 3428  [email protected]